Pfizer  logo
Pfizer PFE
$ 26.57 0.45%

Quarterly report 2026-Q1
added 05-05-2026

report update icon

Pfizer Financial Ratios 2011-2026 | PFE

Annual Financial Ratios Pfizer

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

19.9 18.4 73.5 7.6 11.9 19.4 12.0 20.8 10.0 25.1 25.7 20.6 9.1 13.3 16.0

P/S

2.5 2.3 2.6 2.3 3.2 4.3 3.8 4.3 4.1 3.4 3.7 3.8 3.9 3.3 2.4

EPS

1.4 1.4 0.4 5.6 3.9 1.6 2.9 1.9 3.6 1.2 1.1 1.4 3.2 2.0 1.3

EV (Enterprise Value)

275 B 272 B 290 B 339 B 363 B 267 B 299 B 326 B 313 B 290 B 277 B 282 B 293 B 288 B 262 B

EBITDA per Share

1.16 1.24 1.11 0.9 0.93 0.84 3.33 3.4 3.16 2.92 2.7 2.76 3.08 3.11 3.04

EV/EBITDA

69.3 19.4 13.3 13.6 13.5 12.4 12.8 12.6 11.1 9.6 8.2

PEG

2.76 -2.86 -8.0 -0.61 -1.18 -1.83 0.22 -0.44 0.05 5.67 -1.19 -0.37 0.14 0.25 0.66

P/B

1.8 1.7 1.7 2.5 3.4 2.8 3.1 3.7 3.0 3.0 2.8 2.6 2.6 2.4 1.9

P/CF

13.2 11.6 17.9 8.1 8.0 12.3 19.6 17.0 15.0 13.0 13.7 12.3 12.2 12.4 8.6

ROE %

8.99 9.11 2.37 32.71 28.37 14.43 25.77 17.59 29.88 12.12 10.75 12.81 28.83 17.93 12.18

ROA %

3.73 3.76 0.94 15.91 12.11 5.94 9.72 7.00 12.40 4.20 4.16 5.40 12.78 7.84 5.32

ROCE %

- - - - - - 10.69 11.79 9.98 9.77 9.40 9.14 11.00 11.45 11.36

Current Ratio

1.7 1.7 1.7 1.9 1.7 1.7 0.9 1.6 1.4 1.3 1.5 2.7 2.4 2.1 2.1

DSO

68.1 66.1 69.0 40.5 43.6 73.0 85.1 77.6 78.3 77.8 81.0 63.8 66.2 133.5 125.1

DIO

244.3 215.1 140.2 95.9 101.3 351.3 295.9 243.6 246.1 200.8 284.2 215.8 234.8 227.5 188.0

DPO

123.5 126.2 98.9 65.8 58.5 183.5 150.7 151.7 151.2 134.3 137.0 131.1 123.1 137.3 92.8

Operating Cycle

312.3 281.2 209.2 136.3 144.9 424.2 381.0 321.2 324.4 278.7 365.2 279.6 301.0 361.0 313.0

Cash Conversion Cycle

188.8 155.0 110.3 70.5 86.3 240.8 230.2 169.5 173.2 144.4 228.3 148.5 177.8 223.6 220.2

All numbers in USD currency

Quarterly Financial Ratios Pfizer

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

0.47 0.62 0.51 0.52 0.79 0.01 0.55 -0.42 0.41 0.98 - 1.54 1.77 1.4 - 1.45 0.99 0.87 - 0.26 0.63 0.6 - 1.38 0.91 0.69 - 0.7 0.66 0.6 - 0.48 0.52 0.52 - 0.22 0.34 0.49 - 0.35 0.43 0.38 - 0.42 0.46 0.36 - 0.39 2 0.38 - 0.43 0.44 0.24 - 0.48 0.33 0.28

EBITDA per Share

0.28 0.29 0.29 0.29 0.31 0.31 0.31 - - 0.26 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0.17 0.17 0.25 - 0.75 0.52 0.29 - 0.85 0.55 0.26

ROE %

13.35 15.19 11.43 11.51 5.79 3.31 8.73 14.64 26.35 35.33 30.10 40.83 42.28 38.87 25.74 28.06 19.66 17.27 13.15 25.31 35.15 37.62 26.31 32.79 27.12 25.23 18.21 22.19 19.69 17.89 12.67 14.94 13.24 12.37 10.82 14.11 15.12 15.74 11.02 14.76 15.21 15.23 11.09 14.48 14.14 28.53 25.47 29.42 29.97 15.50 10.16 14.71 15.31 14.48 10.43 4.55 3.18 2.70

ROA %

5.83 6.57 4.89 4.89 2.35 1.38 4.19 7.19 12.70 16.72 13.76 18.30 18.44 16.64 10.89 11.84 8.25 7.24 5.39 9.98 13.61 14.36 9.92 12.50 10.49 9.91 7.24 8.90 7.97 7.33 5.26 6.05 5.18 4.59 3.75 5.03 5.51 5.88 4.26 5.84 6.14 6.29 4.67 6.18 6.11 12.58 11.29 13.02 13.24 6.80 4.44 6.43 6.69 6.33 4.56 1.99 1.39 1.18

Current Ratio

1.8 1.8 1.8 1.8 1.7 1.7 1.7 1.8 1.8 2.1 1.9 1.9 1.8 1.8 1.7 1.7 1.7 1.8 1.7 1.7 1.7 1.7 1.6 1.6 1.6 1.6 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.5 1.5 1.5 1.5 1.6 1.6 1.6 1.6 1.8 1.7 1.7 1.7 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8

DSO

84.8 72.2 74.5 87.5 66.6 76.9 67.7 72.1 79.0 57.4 - 62.9 46.7 43.9 - 42.7 49.4 55.9 - 70.4 73.4 66.5 - 62.8 60.0 58.2 - 55.1 54.4 57.4 - 57.0 58.2 - - - - - - - - - - - 7488.6 8939.5 - 67.5 8370.9 9620.6 - 80.7 77.8 78.0 - 71.7 71.6 -

DIO

284.6 253.0 272.0 362.0 200.8 308.9 284.9 101.0 279.8 173.0 - 150.2 107.8 87.0 - 80.8 113.7 181.2 - 365.8 402.1 355.4 - 290.5 293.4 296.1 - 254.3 234.9 268.6 - 243.1 260.0 - - - - - - - - - - - - 263.9 - 246.0 251.0 246.8 - 240.1 252.3 227.3 - 176.9 162.8 -

DPO

122.5 111.4 125.7 169.2 90.3 147.9 147.6 56.2 172.0 120.8 - 93.9 61.8 50.6 - 41.5 54.7 91.6 - 195.9 215.3 192.8 - 148.0 149.5 166.8 - 158.3 146.3 166.1 - 149.4 159.7 - - - - - - - - - - - - 143.8 - 129.0 131.6 124.1 - 115.4 138.0 132.0 - 98.5 90.1 -

Operating Cycle

369.4 325.2 346.5 449.5 267.4 385.7 352.5 173.1 358.9 230.4 - 213.2 154.5 130.9 - 123.5 163.1 237.1 - 436.2 475.4 422.0 - 353.3 353.4 354.4 - 309.4 289.3 326.0 - 300.1 318.1 - - - - - - - - - - - 7488.6 9203.4 - 313.6 8621.8 9867.4 - 320.8 330.1 305.2 - 248.7 234.4 -

Cash Conversion Cycle

246.8 213.8 220.8 280.2 177.1 237.8 205.0 116.9 186.8 109.6 - 119.3 92.7 80.3 - 82.0 108.4 145.5 - 240.3 260.1 229.2 - 205.3 203.9 187.6 - 151.1 143.1 159.9 - 150.7 158.4 - - - - - - - - - - - 7488.6 9059.7 - 184.5 8490.2 9743.4 - 205.4 192.2 173.2 - 150.2 144.3 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Pfizer , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.13 0.16 % $ 651 M usaUSA
Exelixis Exelixis
EXEL
$ 46.2 4.01 % $ 12.5 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.49 1.22 % $ 69.5 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 6.85 1.93 % $ 196 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.28 2.24 % $ 146 M usaUSA
Galapagos NV Galapagos NV
GLPG
$ 28.82 1.51 % $ 2.69 B belgiumBelgium
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.4 1.51 % $ 6.83 B spainSpain
Genprex Genprex
GNPX
$ 0.89 0.28 % $ 830 K usaUSA
BioNTech SE BioNTech SE
BNTX
$ 94.21 -1.35 % $ 27.2 B germanyGermany
InflaRx N.V. InflaRx N.V.
IFRX
$ 2.37 20.05 % $ 152 M germanyGermany
Immuron Limited Immuron Limited
IMRN
$ 0.82 3.97 % $ 6.82 M australiaAustralia
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
$ 76.34 1.45 % $ 12.2 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.49 3.83 % $ 235 M franceFrance
INmune Bio INmune Bio
INMB
$ 1.51 -1.95 % $ 37.4 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.31 1.22 % $ 260 M israelIsrael
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 85.92 3.88 % $ 7.26 B usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 12.98 -3.53 % $ 1.72 B australiaAustralia
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 23.02 2.98 % $ 3.81 B usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
$ 41.73 3.97 % $ 3.59 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.56 1.71 % $ 5.86 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 106.77 0.9 % $ 5.36 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
MannKind Corporation MannKind Corporation
MNKD
$ 3.88 35.49 % $ 1.19 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
$ 0.27 -3.84 % $ 660 M britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.63 0.9 % $ 3.01 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 39.36 13.2 % $ 286 B franceFrance
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA